We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthpeak Properties' Strong Performance Leads to '24 Guidance Raise
Read MoreHide Full Article
Healthpeak Properties (DOC - Free Report) recently announced that it has increased its 2024 guidance due to the strong performance of its high-quality lab, outpatient medical (OM) and continuity care retirement community (CCRC) portfolio.
Healthpeak now expects funds from operations (FFO) as adjusted per share in the range of $1.80-$1.82, up from the $1.79-$1.81 range guided earlier. The Zacks Consensus Estimate is currently pegged at $1.80 per share. DOC expects total merger-combined same-store cash (adjusted) net operating income (NOI) growth of 4.0%-5.0% compared with the prior expectation of 3.5%-4.5%.
Healthpeak Properties Witnesses Strong Demand
Since the beginning of 2024 through Nov. 18, 2024, Healthpeak has executed around 1.7 million square feet of leases in its lab portfolio. During the same period, DOC has executed 5.3 million square feet of leases in its outpatient medical portfolio.
The increasing life expectancy of the U.S. population and biopharma drug development growth opportunities have promoted the lab real estate market fundamentals. Healthpeak’s focus on the lab segment is a strategic fit, and it expects the majority of its future growth to be driven by such assets. An increasing healthcare expenditure resulting from a rise in senior citizens’ population in the years ahead provides a strong upside potential for Healthpeak’s CCRC portfolio.
Healthpeak has recycled capital through dispositions of non-core assets to acquire and fund the development of lab and outpatient medical assets in high barrier-to-entry markets. As per the November presentation, DOC has sold off 72 non-core assets for $876 million, fortifying its leading OM portfolio with retained assets enjoying enhanced occupancy of 96%.
An under-levered balance sheet provides room for easy availability of debt to fund accretive investments. Healthpeak has been taking steps to bolster its near-term liquidity. As of Nov. 18, 2024, the company had a total liquidity of around $3 billion and a net debt-to-adjusted EBITDAre of 5.1X, with a weighted average debt maturity of 4.4 years and a weighted average interest rate of 3.7%.
Analysts also seem positive about this Zacks Rank #3 (Hold) company, with the Zacks Consensus Estimate for its 2024 FFO per share being raised marginally northward to $1.80 over the past month. Shares of DOC have risen 5.4% year to date compared with the industry’s upside of 2.8%.
The Zacks Consensus Estimate for Cousins Properties’ 2024 FFO per share stands at $2.68, which indicates an increase of 2.3% from the year-ago reported figure.
The Zacks Consensus Estimate for Welltower’s 2024 FFO per share is pegged at $4.26, which suggests year-over-year growth of 17.0%.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Healthpeak Properties' Strong Performance Leads to '24 Guidance Raise
Healthpeak Properties (DOC - Free Report) recently announced that it has increased its 2024 guidance due to the strong performance of its high-quality lab, outpatient medical (OM) and continuity care retirement community (CCRC) portfolio.
Healthpeak now expects funds from operations (FFO) as adjusted per share in the range of $1.80-$1.82, up from the $1.79-$1.81 range guided earlier. The Zacks Consensus Estimate is currently pegged at $1.80 per share. DOC expects total merger-combined same-store cash (adjusted) net operating income (NOI) growth of 4.0%-5.0% compared with the prior expectation of 3.5%-4.5%.
Healthpeak Properties Witnesses Strong Demand
Since the beginning of 2024 through Nov. 18, 2024, Healthpeak has executed around 1.7 million square feet of leases in its lab portfolio. During the same period, DOC has executed 5.3 million square feet of leases in its outpatient medical portfolio.
The increasing life expectancy of the U.S. population and biopharma drug development growth opportunities have promoted the lab real estate market fundamentals. Healthpeak’s focus on the lab segment is a strategic fit, and it expects the majority of its future growth to be driven by such assets. An increasing healthcare expenditure resulting from a rise in senior citizens’ population in the years ahead provides a strong upside potential for Healthpeak’s CCRC portfolio.
Healthpeak has recycled capital through dispositions of non-core assets to acquire and fund the development of lab and outpatient medical assets in high barrier-to-entry markets. As per the November presentation, DOC has sold off 72 non-core assets for $876 million, fortifying its leading OM portfolio with retained assets enjoying enhanced occupancy of 96%.
An under-levered balance sheet provides room for easy availability of debt to fund accretive investments. Healthpeak has been taking steps to bolster its near-term liquidity. As of Nov. 18, 2024, the company had a total liquidity of around $3 billion and a net debt-to-adjusted EBITDAre of 5.1X, with a weighted average debt maturity of 4.4 years and a weighted average interest rate of 3.7%.
Analysts also seem positive about this Zacks Rank #3 (Hold) company, with the Zacks Consensus Estimate for its 2024 FFO per share being raised marginally northward to $1.80 over the past month. Shares of DOC have risen 5.4% year to date compared with the industry’s upside of 2.8%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks from the broader REIT sector are Cousins Properties (CUZ - Free Report) and Welltower (WELL - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Cousins Properties’ 2024 FFO per share stands at $2.68, which indicates an increase of 2.3% from the year-ago reported figure.
The Zacks Consensus Estimate for Welltower’s 2024 FFO per share is pegged at $4.26, which suggests year-over-year growth of 17.0%.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.